d2c9b21d-0f64-4182-9d5d-82b80a158a1f
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.400
- PANCREAS_BETA_CELLS+0.300
- MYOGENESIS+0.200
- CHOLESTEROL_HOMEOSTASIS+0.100
- SPERMATOGENESIS+0.100
- APICAL_JUNCTION+0.000
- APICAL_SURFACE+0.000
- BILE_ACID_METABOLISM+0.000
- ESTROGEN_RESPONSE_LATE+0.000
- HEDGEHOG_SIGNALING+0.000
Top 10 suppressed
- PROTEIN_SECRETION-0.600
- ANDROGEN_RESPONSE-0.500
- G2M_CHECKPOINT-0.500
- MITOTIC_SPINDLE-0.500
- MTORC1_SIGNALING-0.500
- MYC_TARGETS_V1-0.500
- TGF_BETA_SIGNALING-0.500
- UNFOLDED_PROTEIN_RESPONSE-0.500
- UV_RESPONSE_DN-0.500
- APOPTOSIS-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1797231 | — | cohortSC | 0.931 |
| 2 | MDT-AP-2026 | Med | Medulloblastoma | 0.930 |
| 3 | 12183b9e-ecf0-4eaa-9422-157dfa09a66b | — | — | 0.925 |
| 4 | SRR1316535 | GTEX | — | 0.923 |
| 5 | SRR1444460 | GTEX | — | 0.919 |
| 6 | SRR602927 | GTEX | — | 0.915 |
| 7 | SJEPD007_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.915 |
| 8 | SJEPD001520_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.912 |
| 9 | 4e64826b-fffb-4430-bc34-ea6086e89a0a | — | — | 0.911 |
| 10 | SRR1311794 | GTEX | — | 0.909 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 5 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.400 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |